Assignee
AVEO PHARMACEUTICALS INC
US·31 granted patents·21 pending applications·150 citations·filing 2004–2025
Top patents by PatentIndex Score
52 records- 0195US7649083B2Hepatocyte growth factor (HGF) binding antibodyAVEO PHARMACEUTICALS INC·Filed 2007·Granted Jan 19, 2010·29 cites·9 claims
- 0293US7659378B2Hepatocyte growth factor (HGF) binding antibodyAVEO PHARMACEUTICALS INC·Filed 2007·Granted Feb 9, 2010·17 cites·7 claims
- 0392US9175076B2Anti-GDF15 antibodiesAVEO PHARMACEUTICALS INC·Filed 2013·Granted Nov 3, 2015·16 cites·11 claims
- 0491US11725047B2Anti-GDF-15 antibodiesAVEO PHARMACEUTICALS INC·Filed 2020·Granted Aug 15, 2023·2 cites·20 claims
- 0591US9879083B2Anti-Notch3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2013·Granted Jan 30, 2018·12 cites·23 claims
- 0691US9725505B2Methods of treatment using anti-GDF15 antibodiesAVEO PHARMACEUTICALS INC·Filed 2015·Granted Aug 8, 2017·9 cites·36 claims
- 0789US10745476B2Anti-NOTCH3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2018·Granted Aug 18, 2020·5 cites·28 claims
- 0889US7935502B2Hepatocyte growth factor (HGF) binding proteinsAVEO PHARMACEUTICALS INC·Filed 2009·Granted May 3, 2011·7 cites·12 claims
- 0986US12486332B2Anti-ERBB3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2023·Granted Dec 2, 2025·0 cites·15 claims
- 1086US12258391B2Anti-GDF-15 antibodiesAVEO PHARMACEUTICALS INC·Filed 2023·Granted Mar 25, 2025·0 cites·18 claims
- 1186US10597444B2Anti-GDF15 antibodiesAVEO PHARMACEUTICALS INC·Filed 2017·Granted Mar 24, 2020·4 cites·9 claims
- 1286US10494441B2Anti-ERBB3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2017·Granted Dec 3, 2019·4 cites·7 claims
- 1386US7943344B2Hepatocyte growth factor (HGF) binding proteinsAVEO PHARMACEUTICALS INC·Filed 2009·Granted May 17, 2011·6 cites·11 claims
- 1485US9228021B2Anti-ErbB3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2013·Granted Jan 5, 2016·6 cites·39 claims
- 1584US11142573B2Anti-Notch3 antibodyAVEO PHARMACEUTICALS INC·Filed 2017·Granted Oct 12, 2021·2 cites·35 claims
- 1683US7544476B1Identifying cancers sensitive to treatment with inhibitors of notch signalingAVEO PHARMACEUTICALS INC·Filed 2009·Granted Jun 9, 2009·11 cites·9 claims
- 1780US9598498B2Anti-ErbB3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2016·Granted Mar 21, 2017·2 cites·24 claims
- 1879US2026053791A1Use of tivozanib to treat subjects with refractory cancerAVEO PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1978US7736861B1Tivozanib response predictionAVEO PHARMACEUTICALS INC·Filed 2009·Granted Jun 15, 2010·5 cites·4 claims
- 2076US9828635B2Predicting tumor response to anti-ERBB3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2012·Granted Nov 28, 2017·4 cites·8 claims
- 2176US7615353B1Tivozanib response predictionAVEO PHARMACEUTICALS INC·Filed 2009·Granted Nov 10, 2009·1 cites·6 claims
- 2276US2025275955A1Use of tivozanib to treat subjects with refractory cancerAVEO PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2376US2025277019A1Anti-gdf-15 antibodiesAVEO PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2476US2026035457A1Anti-notch3 antibodyAVEO PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2574US2023295285A1Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agentAVEO PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2673US11680108B2Anti-ErbB3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2019·Granted Jun 20, 2023·0 cites·16 claims
- 2773US9096664B2Nucleic acid encoding hepatocyte growth factor (HGF) binding proteinsAVEO PHARMACEUTICALS INC·Filed 2013·Granted Aug 4, 2015·1 cites·23 claims
- 2873US2025289884A1Anti-notch3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2972US12338282B2Anti-Notch3 antibodyAVEO PHARMACEUTICALS INC·Filed 2021·Granted Jun 24, 2025·0 cites·13 claims
- 3072US2022403015A1Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulatorAVEO PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3170US8373017B2Reconstituted human breast tumor modelAVEO PHARMACEUTICALS INC·Filed 2005·Granted Feb 12, 2013·4 cites·6 claims
- 3269US12269877B2Anti-notch3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2020·Granted Apr 8, 2025·0 cites·18 claims
- 3369US11504365B2Use of tivozanib to treat subjects with refractory cancerAVEO PHARMACEUTICALS INC·Filed 2022·Granted Nov 22, 2022·0 cites·12 claims
- 3468US2025019447A1Combination therapy for treatment of cancerAVEO PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3566US2019292253A1Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agentAVEO PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3664US7556796B2Directed complementationAVEO PHARMACEUTICALS INC·Filed 2006·Granted Jul 7, 2009·2 cites·12 claims
- 3764US2014178934A1Hepatocyte growth factor (hgf) binding proteinsAVEO PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 3859US8829164B2Anti-ron antibodiesAVEO PHARMACEUTICALS INC·Filed 2013·Granted Sep 9, 2014·0 cites·11 claims
- 3959US2013165343A1Identification of multigene biomarkersAVEO PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 4058US11897948B2Treatment of chronic kidney disease and other renal dysfunction using a GDF15 modulatorAVEO PHARMACEUTICALS INC·Filed 2018·Granted Feb 13, 2024·0 cites·27 claims
- 4158US2013165337A1Identification of multigene biomarkersAVEO PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 4257US2019292251A1Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulatorAVEO PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4356US2014045715A1Tivozanib response predictionAVEO PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 4454US2022000858A1Use of tivozanib to treat subjects with refractory cancerAVEO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4553US2017306008A1Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agentAVEO PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4653US2013288305A1Anti-fgfr2 antibodiesAVEO PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 4751US7622630B2Chimeric cancer modelsAVEO PHARMACEUTICALS INC·Filed 2004·Granted Nov 24, 2009·1 cites·6 claims
- 4847US2017137505A1Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulatorAVEO PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4945US2018195120A1Predicting tumor response to anti-erbb3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 5042US2017137506A1Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulatorAVEO PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →